Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Other Non Operating Income (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Other Non Operating Income for 4 consecutive years, with -$5000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Non Operating Income fell 110.2% to -$5000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$190000.0, a 2275.0% decrease, with the full-year FY2025 number at -$190000.0, down 2275.0% from a year prior.
  • Other Non Operating Income was -$5000.0 for Q4 2025 at Phathom Pharmaceuticals, up from -$8000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $49000.0 in Q4 2024 to a low of -$197000.0 in Q3 2023.
  • A 4-year average of -$31000.0 and a median of -$8000.0 in 2024 define the central range for Other Non Operating Income.
  • Peak YoY movement for Other Non Operating Income: surged 450.0% in 2024, then tumbled 2483.33% in 2025.
  • Phathom Pharmaceuticals' Other Non Operating Income stood at -$90000.0 in 2022, then skyrocketed by 84.44% to -$14000.0 in 2023, then soared by 450.0% to $49000.0 in 2024, then tumbled by 110.2% to -$5000.0 in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Other Non Operating Income are -$5000.0 (Q4 2025), -$8000.0 (Q3 2025), and -$155000.0 (Q2 2025).